GlassScriptPhysician profile
Chun Kit Chan
NPI 1730284308
$57,165.93
in general payments reported to CMS, 2019-2025
22 companies · $6,221 in 2025
The $6,221 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,984 · 2021: $7,365 · 2022: $5,846 · 2023: $8,211 · 2024: $9,188 · 2025: $6,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $5,451 · Travel and Lodging: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,590.00 |
| Food and Beverage | $5,450.72 |
| Travel and Lodging | $579.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $49,681.38 | 2019-2025 | Vemlidy |
| Amgen INC. | $1,286.59 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,282.27 | 2020-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $959.71 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $682.34 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $567.19 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $424.88 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $405.44 | 2019-2023 | Steglatro, Steglujan, Segluromet |
| Exact Sciences Corporation | $315.33 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $283.72 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $263.91 | 2019-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $173.84 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $172.98 | 2019-2021 | |
| Pfizer INC. | $155.33 | 2019-2024 | |
| Amarin Pharma, INC. | $139.41 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82.54 | 2021-2025 | |
| Corium, LLC | $77.31 | 2023 | Adlarity |
| Horizon Therapeutics Plc | $52.91 | 2023 | Krystexxa |
| Seqirus USA INC | $50.49 | 2024-2025 | Flucelvax, Fluad |
| Kowa Pharmaceuticals America, INC. | $50.18 | 2024-2025 | Zoryve |
| Insmed, INC. | $40.51 | 2019-2025 | Arikayce |
| Arbor Pharmaceuticals, INC. | $17.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chun Kit Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.